Business
Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent
Carlsbad, CA, March 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing
About this update from Palisade Bio, Inc.
[{"type":"text","content":"Carlsbad, CA, March 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that European Patent Office (EPO) has issued a notice of intention to grant for its patent application titled, “Administration of Serine Protease Inhibitors to the Stomach.” Based on the intention to grant notice, the Company expects the EPO to issue a patent in the second half of 2023. In addition to this European patent, the Company continues to bolster its global intellectual property portfolio surrounding LB1148 with submitted and planned submissions of additional patent applications. “We are pleased to receive this encouraging feedback from the EPO for our LB1148 patent and look forward to adding a granted patent to our growing IP portfolio. We believe LB1148 represents a global opportunity and are therefore committed to bolstering its global IP protection as we continue to advance the development of LB1148 for treatment in reducing post-surgical abdominal adhesions,” commented J.D. Finley, interim Chief Executive Officer of Palisade Bio. The patent application, with application number 19209258, for which the EPO has issued an Intention to Grant notice, relates to Palisade Bio’s proprietary compositions for oral administration. The applications contains allowed claims directed to liquid formulations, along with additional claims directed to the use of these formulations in treating shock, a life-threatening complication in situations associated with trauma including burns, surgery, ischemia, sepsis, and other critical care applications. In clinical studies, the Company’s lead program, LB1148 has demonstrated promising results in reducing the incidence and severity of post-surgical abdominal adhesions and accelerating the time to return of postoperative bowel function. LB1148 is currently being evaluated in a Phase 2 study for its effectiveness in reducing intra-abdominal adhesions, accelerating return of gastrointestinal function, and the prevention of post-operative ileus in subjects undergoing elective bowel resection (PROFILE). Palisade expects to report topline data in the first half of 2023. About Palisade Bio Palisade Bio is a biopharmaceutical company focused on developing therapeuti...